Consistent with the above results, CD36 expression was significantly increased following trastuzumab treatment, accompanied by a significant decrease in ERBB2 expression, in post-trastuzumab patients in the TRUP trial (Fig. 1B), confirming the ability of anti-HER2 therapy to upregulate FA uptake in HER2 + BC cells. The gene discussed is ERBB2; the disease is breast cancer.